Methods and analysis:
We will conduct a retrospective cohort study in two Irish PICUs using clinical information on patient characteristics, sedation scores and drug use. Eligible children admitted between January 2014 and June 2016 who were mechanically ventilated and received an opioid infusion will be included. Patients will be categorised into two exposure categories (received an α 2 agonist or did not receive an α 2 agonist) and the time adequately sedated (measured using the COMFORT Behaviour Score) will be calculated using interpolation of nursing sedation scores at each recorded time point. At least 150 per group is planned for inclusion to ensure adequate study power. Propensity score matching will be used in analysis to account for potential confounding by indication. 
Ethics and dissemination:
The study has been approved by the ethics committees of both hospitals. Dissemination will occur via local, national and international presentations for academic and healthcare audiences as well through peer reviewed publications.
__________________________________________________________________________________________________________

Strengths and Limitations of this study
• Both clonidine and dexmedetomidine are in routine use in children with limited information on efficacy; this study examines effectiveness based on clinical data from a large cohort of patients from two PICUs.
• Both PICUs use a validated sedation score: the COMFORT Behaviour score, which allows calculation of a sedation based primary outcome to determine sedative effectiveness of α 2 agonists; an outcome which studies to date have yet to evaluate.
• The PICU population is heterogeneous which may lead to confounding by indication due to the non-randomised design of the study. To minimise the influence of confounding we will use statistical techniques such as propensity scores to adjust our findings for the most important confounders.
• Neither clonidine nor dexmedetomidine are licensed for use in children nor have their optimal dosage regimens been defined. . A sub study will evaluate dose response relationships for different dose bands of each agent. 
Introduction:
Distress and anxiety management is an integral part of paediatric critical care and can be achieved by non-pharmacological and pharmacological interventions. The use of sedatives is important to modifying stressors in the environment and to promote comfort in the ill child. 1 Over 90% of mechanically ventilated children receive sedatives as part of treatment. 2 These are used to maintain comfort, facilitate stressful interventions, attenuate the stress response and reduce metabolic demands during periods of cardiac, respiratory and neurologic instability. 3 4 The practice of sedation itself is a clinical balance between both states of under and over-sedation which represent hazards to the critically ill child.
Under-sedation may lead to distress and adverse events such as unintentional extubation or displacement of catheters as well as increased lengths of stay. 5 6 Conversely, over-sedation can cause cardiovascular depression and ileus, may interfere with comprehensive neurologic examinations and, with prolonged sedation, tolerance and withdrawal phenomena may occur. 6 7 Pharmacological interventions are the cornerstone to achievement of adequate sedation and analgesia. Consensus statements for critically ill children recommend continuous infusions of morphine or fentanyl for relief of severe pain. 1 Opioids are the preferred analgesics because of their marked useful sedative effects. 8 Combination therapy of analgesics and other sedatives are often required in clinical practice with midazolam and other benzodiazepines commonly co-prescribed. 9 Yet, opioids and benzodiazepines are well known to produce tolerance, dependence, and a number of unwanted side effects including cardiovascular and respiratory depression in children. 10 Animal studies also suggest the risk of neurotoxicity and impaired neurodevelopment with use of these agents. 11 It is unclear whether this translates to impairment of human cognitive and functional outcomes. 11 The however create a subset of sedated infants who are potentially at greater risk of longer term cognitive impairment. 12 Alternative sedative options are available through the use of α 2 agonists. 1 Their alternative mode of action has been reported to deliver a lighter sedation with less potential for unwanted adverse effects as seen with traditional agents. 13 14 Both clonidine and dexmedetomidine are α 2 agonists in routine use in clinical practice in an offlabel manner, similar to many analgesics and sedatives. 15 Clonidine, licensed as an antihypertensive in adults, was the first α 2 agonist to enter use as a sedative in paediatrics though lack of dosing information and formulation availability limit its potential use.
Dexmedetomidine is eight times more selective than clonidine for the α 2 over the α 1 receptor and thus may confer less unwanted adverse effects. It is also licensed in adults for ICU sedation and has a shorter half-life allowing easier titration of infusions to sedative effect.
The goal of sedation therapy is to have most patients free of distress, safe and somewhat interactive with their environment. 2 This should ideally be achieved with the minimal amount of medications possible. The level of sedation reached can be assessed by sedation assessment scales and should be reassessed regularly to ensure that the optimal level of sedation is maintained. 16 18-20 The COMFORT Behaviour Scale has good internal consistency with a Cronbach's alpha estimated at 0.84 in a validation study of 78 patients. 16 Nurses displayed high inter-observer validity with a median linearly weighted
Cohen's kappa of 0.84 (range 0.67-0.96) for 52 nurses. 16 Medication adjustments are recommended at scores of <11 and ≥17 for subsequent risk of over and under-sedation respectively. 21 22 Those scores in between are considered to be representative of an adequately sedated state.
Despite their frequent use in critically ill children, the real additive value of using clonidine or dexmedetomidine for sedation is not yet established. 23 A Cochrane review in adults showed that dexmedetomidine reduced the duration of mechanical ventilation (-22%) and intensive care stay (-14%) when compared with standard sedation regimens. 24 Our recent systematic review summarises the current evidence on efficacy of clonidine and dexmedetomidine as sedatives in paediatric critical care. 25 The review highlighted the current lack of evidence from randomised controlled trials supporting efficacy of either agent. The United States Food and Drug Administration have advocated for quality of sedation based outcomes in the determination of efficacy of sedative drugs in paediatrics using validated sedation assessment scales such as the COMFORT Score. 16 studies of the α 2 agonist dexmedetomidine used proportions of time at target sedation levels as their primary outcome using validated sedation scales. 27 In contrast, only one included study in the systematic review of paediatric trials used a validated clinical sedation score based outcome and this study evaluating clonidine efficacy failed to meet the planned recruitment numbers. 28 The remaining studies used primary outcomes based on other measures such as potential opioid sparing effects or duration or mechanical ventilation. [29] [30] [31] [32] [33] The systematic review also described some reports outlining the potential for clonidine to reduce opioid and benzodiazepine co-administration in mechanically ventilated children and for dexmedetomidine to allow for shorter time to extubation after surgery in children. 25 Furthermore, the optimal dosage strategies for both clonidine and dexmedetomidine remains undefined which limit their potential benefit in clinical practice. This needs to be addressed before further interventional studies are planned.
Given the importance of achieving adequate sedation in critical care, the lack of existing evidence from published randomised controlled trials, the lack of studies which used sedation based outcomes, and the routine use of α 2 agonists in clinical practice, we plan to conduct a multi-site retrospective cohort observational study of effectiveness within the two largest Irish PICUs. Applying the design and analysis principles of the adult dexmedetomidine trials, we will utilise a robust design of primarily evaluating noninferiority of time adequately sedated comparing mechanically ventilated children who received an α 2 agonist (either clonidine or dexmedetomidine) to a control group receiving opioids and benzodiazepines. 27 If non-inferiority holds, secondary outcomes will then evaluate any additional opioid or benzodiazepine sparing effect conferred by the additional of the α 2 agonists. The study period is planned to be over a two year period 1 January 2014 to 30 June 2016.
These dates have been chosen based on the availability of an adequately large patient population whom will have been exposed to the study drugs as well as coinciding with the availability of electronic patient information. The observation period when data for outcomes will be recorded is that during which the patient is mechanically ventilated as shown in Figure 1 . The start time for the α 2 agonist group will be from the time of the first administration of either clonidine or dexmedetomidine (T2a) .The end time will be the time of end of mechanical ventilation (T3). Proportion of the time from T2a to T3 judged to be adequately sedated will be calculated for the primary outcome comparison. The period of time (hours) from beginning of mechanical ventilation (T1) to first administration of an α 2 agonist (T2a)
will be recorded and included as a time-varying co-variant in subsequent analysis.
For the control group which did not receive an α 2 agonist their corresponding observation period start time (T2c) will be defined as the point at which analgesia and sedation therapy is "stepped up". This will be defined as any of the following 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 • Administration of a rescue morphine or midazolam bolus
• Administration of chloral hydrate
• Commencement of a midazolam infusion
• Increase in background opioid infusion
For this control the corresponding proportion of time from T2c to T3 adequately sedated will also be calculated. The preceding lag time before T2a and T2c will be left censored.
These observation time periods for both groups will be used for calculation of opioid and benzodiazepine use for calculation of secondary outcomes. We will right censor for patients who die or remain in the study at the end of the study period. The left censored lag time will be included in the propensity score model.
Data for clinical details, exposure and outcomes measures will be extracted from a combination of the electronic clinical information systems, local PICANET audit data 34 and hardcopy medical records. Patients will be followed up for the duration of their PICU stay.
The study protocol has been compiled with regard to the STROBE checklist of items to be included in reports of cohort studies. 35 Inclusion and Exclusion Criteria All patient admissions where the patient was mechanically ventilated in the two study PICUs will be allocated a unique encounter identification number. These encounters will then be further screened against the below eligibility to generate a database of potentially eligible patients. All eligible patients from the solely electronic site (Our Lady's Children's Hospital) will be included. The second site (Children's University Hospital) requires additional manual data extraction from medical records. Approximately four months will be spent extracting the extra data from this site sampling randomly across the two year study timeline. The final included patients will be a representative sample of both study sites distributed across the study groups.
Only patients meeting all of the following criteria will be included:
• PICU inpatient between 1 January 2014 and 30 June 2016 at either hospital
• First admission during study time period
• Received mechanical ventilation for greater than 8 hours
• Received an infusion of an opioid
• COMFORT Behaviour Scores recorded (>2 scores)
Patients with one or more of the following criteria will be excluded:
• COMFORT Behaviour Scores not valid [severe neur-developmental delay, severe autism, severe hypotonia or those receiving continuous neuromuscular blockade]
• COMFORT Behaviour Scores not recorded (<2 scores)
• Administered an α 2 agonist for an indication other than sedation
• Administered both clonidine and dexmedetomidine in the same admission Exposure measures For the primary outcome patients will be categorised into two exposure groups (1) α 2 agonist exposed (2) no α 2 agonist exposure (control group) based on the sedative agents administered while mechanically ventilated. Included patients will be described according to the characteristics shown in Table 1 . 
Primary Outcome
The primary outcome of this study is the proportion of time adequately sedated while mechanically ventilated. Level of sedation will be measured using the validated COMFORT Behaviour Score. We define "adequately sedated" as COMFORT Behaviour Scores recorded at 11-16 inclusive as scores outside this range may indicate over-sedation, under-sedation or a requirement for medication adjustment. The recorded time of COMFORT Behaviour Scores at each assessment point will be plotted (See Figure 2) and, by linearly connecting these, we will calculate the time in the respective sedation states: adequately sedated (COMFORT Behaviour Score 11-16), potentially under-sedated (COMFORT Behaviour Score >16) and potentially over-sedated (COMFORT Behaviour Score <11). Sedation protocols in both units recommend assessing clinical sedation scores every four hours while mechanically ventilated. We will investigate patients with very low calculated proportions of time adequately sedated (<20%) to see if they had a different sedation target due to clinical necessity and if so they will be excluded from the analysis. For the rare occasions in our units where morphine is not the primary opioid used we will use the conversion factor morphine 1 mg = fentanyl 15 μg = hydromorphone 0.15 mg. Oral morphine exposure will be halved to account for its reduced bioavailability compared to parenteral opioids when calculating cumulative exposure. 36 • Change in opioid infusion rate from baseline infusion rate to average infusion rate (expressed as morphine μg/kg/hour)
• Midazolam use, infusion and bolus, (expressed as midazolam μg/kg/hour).
• Number of chloral hydrate boluses/24 hours
• Number of paracetamol boluses/24 hours
• Duration of mechanical ventilation (days)
• Duration of PICU stay (days)
Confounding factors
Confounding by indication is an important consideration in pharmacoepidemiological observational studies of drug effects. This type of confounding arises from the fact that patients who are prescribed a medication may be different from those not prescribed the drug. In our context, this may arise if, for example, sicker patients are prescribed clonidine or dexmedetomidine as reserve agents compared to those receiving first line agents like analysis. This creates probability scores for receiving exposures or treatments that allow comparisons to unexposed patients. It is a direct way of adjusting for confounding but relies on the confounders being identifiable and measurable. We will capture a comprehensive list of patient and practice characteristics which will be considered for inclusion as potential confounders in our analyses. Details of potential confounders to be included in the process of constructing a propensity score model are included in the data analysis section. Sedation guidelines within both PICUs leave the decision to use α 2 agonists to individual physician preference which should generate a degree of randomness in the distribution of exposed and unexposed groups as exposure is less influenced by inherent patient characteristics. We will also capture all drug exposure information for patients, diagnoses and co-morbidity alongside severity of illness scores to attempt to further minimise confounding by indication.
Data Analysis Plan
All variable and outcome data will be plotted to assess normality. Normally distributed data will be described by a mean and standard deviation while non-parametric data will be described by medians and interquartile ranges. Tests of statistical significance will be assumed significant at the level of p<0.05.
Matching
We will estimate using a logistic regression the propensity score for receiving treatment with an α 2 agonist. Predicted probability values for being exposed to one drug over the unexposed on a range from 0 to 1 will be estimated using a combination of measured variables (potential confounders) incorporated into the models. Rosenbaum-bounds will then be calculated to determine sensitivity to unmeasured confounders. Matching quality will be assessed for balanced co-variants. Once propensity scores are estimated the outcomes for α 2 agonist exposed patients can be contrasted with outcomes of the control patients. The overlap and region of common support will be checked between the exposed and cohorts. We will then trim the samples by excluding patients corresponding to extremes of propensity score. We will then use 1:1 and nearest neighbour matching with replacement. A maximum difference of 0.2 x Standard Deviation of the propensity score will be set as a calliper interval for distances between propensity score matches. Patient and Hospital level potential confounders which will be included in the process of constructing a propensity score include hospital site, age, weight, gender, pre-existing diseases, severity of illness, risk of mortality and baseline dose of analgesic and sedative drugs.
Primary Outcome Analysis
The proportion of time adequately sedated for the α 2 agonist exposed group (clonidine and dexmedetomidine patients) will be compared to the corresponding proportion for a non α 2 agonist exposed group, mimicking the primary analysis of the adult dexmedetomidine trials. 27 Non-inferiority will be assessed using a two-sided 95% confidence interval for the estimated ratio of proportion of time in range for the exposed and non-exposed groups. If the lower limit of the confidence interval of the estimated α 2 agonist to control group ratio of proportion of time in range is above 0.875 (within the non-inferiority threshold of 12.5%) then non-inferiority is inferred. If the test is successful we will then proceed to analyse the study for a superiority conclusion. No statistical adjustment is required for this planned sequence of analyses. All of the pre-specified secondary outcomes will result in continuous outcome variables.
Secondary Outcome Analyses
Paired t-tests will be used to evaluate differences between treatment groups and unexposed controls. Non-parametric equivalents such as the Mann-Whitney U test will be considered in the event of skewness of data.
Other Analyses
While the primary outcome of this study combines patients who received clonidine and dexmedetomidine into one α 2 agonist cohort we anticipate having a larger sub-cohort of clonidine than dexmedetomidine exposed patients. In secondary analyses we will evaluate the two α 2 agonist sub-groups (clonidine and dexmedetomidine) in terms of the prespecified outcomes. We do not anticipate having enough dexmedetomidine patients to power the study for three independent groups a priori. We will however form a series of triplets of closely matching clonidine, dexmedetomidine and control patients to increase study power and allow inter-drug comparisons between clonidine and dexmedetomidine.
We plan to further analyse by potential effect modifiers such as dose range bands for both agents, matching different dose bands by propensity score ranges and examining for differential responses to highlight potentially favourable dose bands for future studies. We will also evaluate diagnostic category subgroups such as post-surgery and by reason for admission to allow comparisons in more homogenous groups. A sub group analysis for those with and without neuro-developmental disorders is also planned.
Determination of non-inferiority limit
Pilot data from the patient data population estimates the control group is adequately sedated 68% of the time. Allowing for a non-inferiority margin of 12.5% we would accept the test groups to be not inferior when adequately sedated more than 59.5% of the time. This is acceptable both clinically and also this threshold corresponds to two hours less adequately sedated on a 24 hour clock. Anything greater than two hours is likely to be detectable on regular sedation score based nursing monitoring.
Sample size calculation
Taking a conservative estimate of 65% of time adequately sedated (lower than from pilot data) and an acceptable non inferiority limit of 12.5% a sample size of 150 per group would be required to give 90% power when testing our hypothesis. We will therefore require at least 150 patients who received an α 2 agonist and 150 suitable unexposed patients given a total of at least 300 patients in the overall study. As this is retrospective data and we are seeking to enhance the quality of our matching potential we will extract data for more patients as some may need to be excluded when ensuring quality matches. Manual data extraction from charts will be the rate limiting factor that determines our number of included patients over the data extraction period.
Missing Data Due to the observational nature of the study, there will be varying numbers of data points recording COMFORT Behaviour Scores while mechanically ventilated. Protocols in place on both units recommend sedation scoring every four to six hours. We will describe the extent and patterns of COMFORT Behaviour Scores in both units. By design we evaluate proportion of time adequately sedated. This intentionally minimises the impact of some patients having more or less regular scores recorded versus other studies which report number of episodes of over or under-sedation scores. We will also perform a sensitivity analysis excluding those with a low amount of COMFORT Behaviour scores recorded (e.g. <60% expected assessments) Sources of Bias Selection bias would result is a distortion of the measurement of treatment effect due to selection into the study of groups of patients who have an unusual and unequal relationship between drug exposure and outcome. 37 To reduce this risk we include all eligible patients from the larger PICU site at OLCHC. At the second site at TSCUH due to the existence of paper records we will sample randomly from all eligible patients throughout the study period. Due to the nature of monitoring in PICU and the short study time there will be no patients lost to follow up. The fact that sedative choice is influenced by physician preference also reduces the risk of selection bias.
A potential limitation of the COMFORT Behaviour Score is that scoring is based on a two minute observation window and not a longer time period. Secondly the middle area of the COMFORT Behaviour scale is regarded as less reliable for predicting under and over sedation. In particular the value of 11 can be debated to be more likely to represent adequately on not adequately sedated. We initially will consider 11 as adequately sedated based on local practice, but a sensitivity analysis will be carried out to examine the potential implications of classifying the 11 as adequate or inadequately sedated. Exposure to drug may also be time varying. For our initial analysis of effectiveness we will consider exposures as fixed but in future further analysis will evaluate the effect of consideration of exposure as time-varying.
Outcomes
Anticipated effectiveness and safety outcomes from the primary and secondary outcomes are shown in Table 2 . Data will be presented in both unadjusted and adjusted formats. Any differences will be described in clinical and statistical significance. Two articles are currently planned to be submitted to international peer reviewed journals
(1) results from the comparative effectiveness study and (2) results from a sub study looking at dose response relationships with clonidine and dexmedetomidine. The reporting will be in accordance with the "Strengthening the Reporting of Observational Studies in
Epidemiology criteria" (STROBE). 35 Further dissemination of study results is planned for national and international conferences in the area as well as locally in both hospitals for clinical information. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Strengths and Limitations of this study
• Neither clonidine nor dexmedetomidine are licensed for use in children nor have their optimal dosage regimens been defined. A sub study will evaluate dose response relationships for different dose bands of each agent. and neurologic instability. 3 4 The practice of sedation itself is a clinical balance between both states of under and over-sedation which represent hazards to the critically ill child.
___________________________________________________________________________
Under-sedation may lead to distress and adverse events such as unintentional extubation or displacement of catheters as well as increased lengths of stay. 5 6 Conversely, over-sedation can cause cardiovascular depression and ileus, may interfere with comprehensive neurologic examinations and, with prolonged sedation, tolerance and withdrawal phenomena may occur. 6 7 Pharmacological interventions are the cornerstone to achievement of adequate sedation and analgesia. Consensus statements for critically ill children recommend continuous infusions of morphine or fentanyl for relief of severe pain. 1 Opioids are the preferred analgesics because of their marked useful sedative effects. 8 Combination therapy of analgesics and other sedatives are often required in clinical practice with midazolam and other benzodiazepines commonly co-prescribed. 9 Yet, opioids and benzodiazepines are well known to produce tolerance, dependence, and a number of unwanted side effects including cardiovascular and respiratory depression in children. 10 Animal studies also suggest the risk of neurotoxicity and impaired neurodevelopment with use of these agents. 11 It is unclear whether this translates to impairment of human cognitive and functional outcomes. 11 The 12 Alternative sedative options are available through the use of α 2 agonists. 1 Their alternative mode of action has been reported to deliver a lighter sedation with less potential for unwanted adverse effects as seen with traditional agents. 13 14 Both clonidine and dexmedetomidine are α 2 agonists in routine use in clinical practice in an offlabel manner, similar to many analgesics and sedatives. 15 Clonidine, licensed as an antihypertensive in adults, was the first α 2 agonist to enter use as a sedative in paediatrics though lack of dosing information and formulation availability limit its potential use.
The goal of sedation therapy is to have most patients free of distress, safe and somewhat interactive with their environment. 2 This should ideally be achieved with the minimal amount of medications possible. The level of sedation reached can be assessed by sedation assessment scales and should be reassessed regularly to ensure that the optimal level of sedation is maintained. 1 Sedation assessment scales further facilitate titration of sedative medications. One of the most widely used sedation assessment scales is the COMFORT Behaviour Scale. 16 This is a modified version of the original COMFORT Scale 17 which excluded the physiological parameters (blood pressure and heart rate) of the original scale. This leaves a six parameter non-intrusive measure of behaviours designed to assess distress and response to sedatives. Following a two minute observation period the assessor 16 18-20 The COMFORT Behaviour Scale has good internal consistency with a Cronbach's alpha estimated at 0.84 in a validation study of 78 patients. 16 Nurses displayed high inter-observer validity with a median linearly weighted
Despite their frequent use in critically ill children, the real additive value of using clonidine or dexmedetomidine for sedation is not yet established. 23 A Cochrane review in adults showed that dexmedetomidine reduced the duration of mechanical ventilation (-22%) and intensive care stay (-14%) when compared with standard sedation regimens. 24 Our recent systematic review summarises the current evidence on efficacy of clonidine and dexmedetomidine as sedatives in paediatric critical care. 25 The review highlighted the current lack of evidence from randomised controlled trials supporting efficacy of either agent. The United States Food and Drug Administration have advocated for quality of sedation based outcomes in the determination of efficacy of sedative drugs in paediatrics using validated sedation assessment scales such as the COMFORT Score. 16 26 Pivotal adult studies of the α 2 agonist dexmedetomidine used proportions of time at target sedation levels as their primary outcome using validated sedation scales. 27 In contrast, only one included study in the systematic review of paediatric trials used a validated clinical sedation score based outcome and this study evaluating clonidine efficacy failed to meet the planned recruitment numbers. 28 The remaining studies used primary outcomes based on other measures such as potential opioid sparing effects or duration or mechanical ventilation. [29] [30] [31] [32] [33] The systematic review also described some reports outlining the potential for clonidine to reduce opioid and benzodiazepine co-administration in mechanically ventilated children and for dexmedetomidine to allow for shorter time to extubation after surgery in children. 25 Furthermore, the optimal dosage strategies for both clonidine and dexmedetomidine remains undefined which limit their potential benefit in clinical practice. This needs to be addressed before further interventional studies are planned.
Given the importance of achieving adequate sedation in critical care, the lack of existing evidence from published randomised controlled trials, the lack of studies which used sedation based outcomes, and the routine use of α 2 agonists in clinical practice, we plan to conduct a multi-site retrospective cohort observational study of effectiveness within the two largest Irish PICUs. Applying the design and analysis principles of the adult dexmedetomidine trials, we will utilise a robust design of primarily evaluating noninferiority of time adequately sedated comparing mechanically ventilated children who received an α 2 agonist (either clonidine or dexmedetomidine) to a control group receiving opioids and benzodiazepines. 27 If the prerequisite of non-inferiority of quality of sedation holds, secondary outcomes will then evaluate any additional opioid or benzodiazepine sparing effect conferred by the additional of the α 2 agonists.
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These dates have been chosen based on the availability of an adequately large patient population whom will have been exposed to the study drugs as well as coinciding with the availability of electronic patient information. The observation period when data for outcomes will be recorded is that during which the patient is mechanically ventilated as shown in Figure 1 . will be recorded and included as a time-varying co-variant in subsequent analysis.
For the control group which did not receive an α 2 agonist their corresponding observation period start time (T2c) will be defined as the point at which analgesia and sedation therapy is "stepped up". This will be defined as any of the following
• Administration of a rescue morphine or midazolam bolus 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 For this control the corresponding proportion of time from T2c to T3 adequately sedated will also be calculated. The preceding lag time before T2a and T2c will be left censored.
These observation time periods for both groups will be used for calculation of opioid and benzodiazepine use for calculation of secondary outcomes. We will right censor for patients who die or remain in the study at the end of the study period. The left censored lag time will be included in the propensity score model. Long stay patients with study times greater than 28 days will be excluded from the study as they may not be representative of the general PICU population.
The study protocol has been compiled with regard to the STROBE checklist of items to be included in reports of cohort studies. 35 Inclusion and Exclusion Criteria All patient admissions where the patient was mechanically ventilated in the two study PICUs will be allocated a unique encounter identification number. These encounters will then be further screened against the below eligibility to generate a database of potentially eligible patients. All eligible patients from the solely electronic site (Our Lady's Children's Hospital)
will be included. The second site (Children's University Hospital) requires additional manual data extraction from medical records. Approximately four months will be spent extracting the extra data from this site sampling randomly across the two year study timeline. The final included patients will be a representative sample of both study sites distributed across the study groups.
• Study durations greater than 28 days
• Opioid infusions other than morphine Exposure measures For the primary outcome patients will be categorised into two exposure groups (1) α 2 agonist exposed (2) no α 2 agonist exposure (control group) based on the sedative agents administered while mechanically ventilated. Included patients will be described according to the characteristics shown in Table 1 . 
Primary Outcome
The primary outcome of this study is the proportion of time adequately sedated while mechanically ventilated. Level of sedation will be measured using the validated COMFORT Behaviour Score. We define "adequately sedated" as COMFORT Behaviour Scores recorded 36 We will investigate patients with very low calculated proportions of time adequately sedated (<20%) to see if they had a different sedation target due to clinical necessity and if so they will be excluded from the analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Determination of potential benefit of α 2 agonists This study design adopts a hierarchical set of outcomes. Similar to the design of the largest adult trials of sedatives we have set the prerequisite that an α 2 based regimen is noninferior to an opioid/benzodiazepine control regimen before we compare potential benefits such as lessening the amount of other sedatives administered. 27 We believe this is more rigorous than simply describing similarity of average sedation scores. Only if non-inferiority can be confirmed can we explore fully the benefits of an α 2 based regimen. Meeting the primary outcome alone does not form the basis of evidence of α 2 effectiveness but allows us then to evaluate benefits in our secondary outcomes that may provide evidence for potential benefits of α 2 based regimens. The addition of the α 2 agonists may produce a deeper sedation and we will also report on time potentially over and -under sedated for both groups to allow the reader contextualise any secondary outcome benefits with the depth of sedation achieved.
Using as assessment score like the COMFORT Behaviour score as a guiding therapy for sedative use and also as an outcome measure would not usually be an appropriate study design as reactionary and compensatory use of other drugs may artificially increase time adequately sedated. However, in this specific context, similar to the adult dexmedetomidine trials, 27 meeting the primary outcome alone does not determine effectiveness. It is a prerequisite to evaluate other potential benefits in the secondary outcomes. Compensatory use of other drugs to ensure maintenance of target sedation that may occur will be captured by our selected secondary outcomes on opioid and benzodiazepine use. Hence, if this compensation occurs it will be measurable to us and even if the α 2 regimen meets the primary outcome no benefit will be seen in the secondary outcomes and we cannot interpret the results as a sign of α 2 effectiveness. analysis. This creates probability scores for receiving exposures or treatments that allow comparisons to unexposed patients. It is a direct way of adjusting for confounding but relies on the confounders being identifiable and measurable. We will capture a comprehensive list of patient and practice characteristics which will be considered for inclusion as potential confounders in our analyses. Details of potential confounders to be included in the process of constructing a propensity score model are included in the data analysis section. Sedation guidelines within both PICUs leave the decision to use α 2 agonists to individual physician preference which should generate a degree of randomness in the distribution of exposed and unexposed groups as exposure is less influenced by inherent patient characteristics. We will also capture all drug exposure information for patients, diagnoses and co-morbidity alongside severity of illness scores to attempt to further minimise confounding by indication.
Data Analysis Plan
All variable and outcome data will be plotted to assess normality. Normally distributed data will be described by a mean and standard deviation while non-parametric data will be described by medians and interquartile ranges. Tests of statistical significance will be assumed significant at the level of p<0.05. 
Matching
Primary Outcome Analysis
The proportion of time adequately sedated for the α 2 agonist exposed group (clonidine and dexmedetomidine patients) will be compared to the corresponding proportion for a non α 2 agonist exposed group, mimicking the primary analysis of the adult dexmedetomidine trials. 27 Non-inferiority will be assessed using a two-sided 95% confidence interval for the estimated ratio of proportion of time in range for the exposed and non-exposed groups. If the lower limit of the confidence interval of the estimated α 2 agonist to control group ratio 
Secondary Outcome Analyses
All of the pre-specified secondary outcomes will result in continuous outcome variables.
Other Analyses
We plan to further analyse by potential effect modifiers such as dose range bands for both agents, matching different dose bands by propensity score ranges and examining for differential responses to highlight potentially favourable dose bands for future studies. We will also evaluate diagnostic category subgroups such as post-surgery and by reason for Determination of non-inferiority limit Pilot data from the patient data population estimates the control group is adequately sedated 68% of the time. Allowing for a non-inferiority margin of 12.5% we would accept the test groups to be not inferior when adequately sedated more than 59.5% of the time.
This is acceptable both clinically and also this threshold corresponds to two hours less adequately sedated on a 24 hour clock. Anything greater than two hours is likely to be detectable on regular sedation score based nursing monitoring.
Sample size calculation Taking a conservative estimate of 65% of time adequately sedated (lower than from pilot data) and an acceptable non inferiority limit of 12.5% a sample size of 150 per group would be required to give 90% power when testing our hypothesis. We will therefore require at least 150 patients who received an α 2 agonist and 150 suitable unexposed patients given a total of at least 300 patients in the overall study. As this is retrospective data and we are seeking to enhance the quality of our matching potential we will extract data for more patients as some may need to be excluded when ensuring quality matches. Manual data extraction from charts will be the rate limiting factor that determines our number of included patients over the data extraction period.
Missing Data Due to the observational nature of the study, there will be varying numbers of data points recording COMFORT Behaviour Scores while mechanically ventilated. Protocols in place on both units recommend sedation scoring every four to six hours. We will describe the extent and patterns of COMFORT Behaviour Scores in both units. By design we evaluate proportion Sources of Bias Selection bias would result is a distortion of the measurement of treatment effect due to selection into the study of groups of patients who have an unusual and unequal relationship between drug exposure and outcome. 37 To reduce this risk we include all eligible patients from the larger PICU site at OLCHC. At the second site at TSCUH due to the existence of paper records we will sample randomly from all eligible patients throughout the study period. Due to the nature of monitoring in PICU and the short study time there will be no patients lost to follow up. The fact that sedative choice is influenced by physician preference also reduces the risk of selection bias.
A potential limitation of the COMFORT Behaviour Score is that scoring is based on a two minute observation window and not a longer time period. Secondly the middle area of the COMFORT Behaviour scale is regarded as less reliable for predicting under and over sedation. In particular the value of 11 can be debated to be more likely to represent adequately on not adequately sedated. We initially will consider 11 as adequately sedated based on local practice, but a sensitivity analysis will be carried out to examine the potential implications of classifying the 11 as adequate or inadequately sedated. Exposure to drug may also be time varying. For our initial analysis of effectiveness we will consider exposures as fixed but in future further analysis will evaluate the effect of consideration of exposure as time-varying. 
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